Mouse cathelin-related antimicrobial peptide chemoattracts leukocytes using formyl peptide receptor-like 1/mouse formyl peptide receptor-like 2 as the receptor and acts as an immune adjuvant.
Kurosaka. Kahori K; Chen. Qian Q; Yarovinsky. Felix F; Oppenheim. Joost J JJ; Yang. De D
Key Findings
- CRAMP (mouse LL‑37) attracts human and mouse immune cells by binding to the FPRL1/ mouse formyl peptide receptor‑2
- CRAMP triggers calcium signals and MAPK activation in monocytes, indicating functional cell activation
- Injecting CRAMP in mice draws neutrophils and monocytes to the site and improves both antibody and cellular responses to a co‑administered antigen
Practical Outcomes
- For DIY health enthusiasts, this suggests LL‑37 might have immune‑boosting properties beyond its antimicrobial action, but the evidence is limited to mouse studies. No human dosing or safety data are provided, so any self‑experimentation would be speculative and should be approached with caution.
Summary
The mouse version of the human antimicrobial peptide LL‑37 (called CRAMP) can pull immune cells to where it’s needed and boost the body’s response to a vaccine‑like challenge, working through a specific cell‑surface receptor. This shows that LL‑37 isn’t just an antimicrobial; it also helps direct immune cells and can act as an immune‑enhancing agent in mice.
Abstract
Mammalian antimicrobial proteins, such as defensins and cathelicidin, have stimulating effects on host leukocytes. Cathelin-related antimicrobial peptide (CRAMP), the orthologue of human cathelicidin/LL-37, is the sole identified murine cathelicidin. CRAMP has been shown to have both antimicrobial and angiogenic activities. However, whether CRAMP, like human cathelicidin/LL-37, also exhibits a direct effect on the migration and function of leukocytes is not known. We have observed that CRAMP, like LL-37, was chemotactic for human monocytes, neutrophils, macrophages, and mouse peripheral blood leukocytes. CRAMP also induced calcium mobilization and the activation of MAPK in monocytes. CRAMP-induced calcium flux in monocytes was desensitized by MMK-1, an agonistic ligand specific for formyl peptide receptor-like-1 (FPRL1), and vice versa, suggesting the use of FPRL1 by CRAMP as a receptor. Furthermore, CRAMP induced the chemotaxis of human embryonic kidney 293 cells transfected with either FPRL1 or mouse formyl peptide receptor-2, the mouse homologue of FPRL1, but not by untransfected parental human embryonic kidney 293 cells, confirming the use of FPRL1/mouse formyl peptide receptor-2 by CRAMP. Injection of CRAMP into mouse air pouches resulted in the recruitment predominantly of neutrophils and monocytes, indicating that CRAMP acts as a chemotactic factor in vivo. Finally, simultaneous administration of OVA with CRAMP to mice promoted both humoral and cellular Ag-specific immune responses. Thus, CRAMP functions as both a chemoattractant for phagocytic leukocytes and an enhancer of adaptive immune response.
Study Information
pubmed
2005
2005-05-15T00:00:00.000Z
10.4049/jimmunol.174.10.6257
229
73